Literature DB >> 14574457

Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha.

Michael I Koukourakis1, Alexandra Giatromanolaki, Wen Chong, Costantinos Simopoulos, Alexandros Polychronidis, Efthimios Sivridis, Adrian L Harris.   

Abstract

PURPOSE: The cytoprotective mechanism of amifostine (WR-2721) implies free radical scavenging and DNA repair activities. We investigated additional cytoprotective pathways involving intracellular hypoxia and the activation of the hypoxia-inducible factor (HIF) pathway, a key transcription factor regulating glycolysis, angiogenesis and apoptosis, which is also linked with radioresistance.
MATERIALS AND METHODS: The glucose and oxygen levels in the peripheral blood of patients receiving 1000 mg amifostine were determined at various time-points in order to investigate the metabolic changes induced by amifostine. MDA468 breast tumor cell lines were incubated with a high amifostine concentration (10 m M) to overcome the natural resistance of cancer cells to influx of the non-hydrolyzed WR-2721, and the HIF1 alpha protein levels were determined by Western blot analysis. In vivo experiments with Wistar rats were performed in order to assess immunohistochemically changes in the intracellular accumulation of HIF1 alpha induced by amifostine (200 mg/kg).
RESULTS: By 30 min following amifostine administration, the hemoglobin oxygen saturation and pO(2) levels had increased in the peripheral blood while glucose levels had reduced, providing evidence that normal tissue metabolism switches to glycolytic pathways. Incubation of cell lines with amifostine resulted in HIF1 alpha induction. In Wistar rats administration of amifostine resulted in increased HIF1 alpha accumulation in normal tissues.
CONCLUSIONS: Since it is doubtful whether dephosphorylation of amifostine to the active metabolite WR-1065 occurs within tumoral tissues (an acidic environment that lacks vascular alkaline phosphatase activity), intracellular hypoxia and upregulation of HIF1 alpha represents an additional, normal tissue-specific, amifostine cytoprotective pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14574457     DOI: 10.1007/s00280-003-0691-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury.

Authors:  Panfeng Fu; Jeffrey S Murley; David J Grdina; Anna A Birukova; Konstantin G Birukov
Journal:  Crit Care Med       Date:  2011-12       Impact factor: 7.598

2.  Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

Authors:  M I Koukourakis
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

3.  Selenoprotein P inhibits radiation-induced late reactive oxygen species accumulation and normal cell injury.

Authors:  Jaimee C Eckers; Amanda L Kalen; Wusheng Xiao; Ehab H Sarsour; Prabhat C Goswami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-01       Impact factor: 7.038

Review 4.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

5.  The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

Authors:  S Dedieu; X Canron; H R Rezvani; M Bouchecareilh; F Mazurier; R Sinisi; M Zanda; M Moenner; A Bikfalvi; S North
Journal:  BMC Med       Date:  2010-03-24       Impact factor: 8.775

6.  Tissue damage in rat ovaries subjected to torsion and detorsion: effects of L-carnitine and N-acetyl cysteine.

Authors:  Ufuk Usta; Mustafa Inan; Hakan Erbas; Nurettin Aydogdu; Fulya Oz Puyan; Semsi Altaner
Journal:  Pediatr Surg Int       Date:  2008-03-21       Impact factor: 1.827

7.  Does amifostine reduce metabolic rate? Effect of the drug on gas exchange and acute ventilatory hypoxic response in humans.

Authors:  Jaideep J Pandit; Caroline Allen; Evelyn Little; Federico Formenti; Adrian L Harris; Peter A Robbins
Journal:  Pharmaceuticals (Basel)       Date:  2015-04-16

8.  CDDO-Me protects normal lung and breast epithelial cells but not cancer cells from radiation.

Authors:  Mariam El-Ashmawy; Oliver Delgado; Agnelio Cardentey; Woodring E Wright; Jerry W Shay
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

9.  Normal tissue radioprotection by amifostine via Warburg-type effects.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Christos E Zois; Dimitra Kalamida; Stamatia Pouliliou; Ilias V Karagounis; Tzu-Lan Yeh; Martine I Abboud; Timothy D W Claridge; Christopher J Schofield; Efthimios Sivridis; Costantinos Simopoulos; Savvas P Tokmakidis; Adrian L Harris
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

10.  The Role of Recombinant Fibroblast Growth Factor 1 in Enhancing the Angiogenesis in Random Cutaneous Flaps in Animal Model of Rat.

Authors:  Hossein Akbari; Mehdi Ahmadi; Mohammad Javad Fatemi; Ali Foroutan; Peyman Akbari; Hossein Bagheri; Majid Golkar
Journal:  World J Plast Surg       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.